CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
Impact Biomedical's board approved a 1-for-12.62 reverse stock split effective 12:01 a.m. ET on September 23, 2026, cutting shares outstanding from approximately 107,821,231 to 8,543,679. The stock will keep trading on NYSE American under the IBO ticker with a new CUSIP. The split is explicitly intended to support the proposed business combination with Zoar Limited and the company's continued-listing objectives, though the release cautions it does not assure NYSE American listing standards will be met or that the merger will close.
Key figures
- Effective date
- 2026-09-23
- Reverse split ratio
- 1-for-12.62
- Merger exchange ratio
- 1 Zoar share per 1 Impact share after reverse split
- Shares outstanding pre split
- 107821231
- Shares outstanding post split
- 8543679
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.